Compass Therapeutics, Inc. (CMPX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Compass Therapeutics highlighted four oncology drug programs in the clinic, led by tovecimig, a DLL4/VEGF-A bispecific antibody, with secondary endpoint results from a randomized trial already read out and an FDA approach planned for later this summer. The company also said its next-generation CD137 agonist, PD-1/PD-L1 bispecific, and PD-1/VEGF-A bispecific programs have shown responses in post-checkpoint inhibitor patients. The update is constructive but largely developmental and conference-based, so near-term market impact appears limited.

Analysis

CMPX is in the awkward but valuable phase where the market is forced to re-rate the platform, not just the lead asset. The bigger second-order implication is that management is effectively presenting four shots on goal across distinct biology stacks, which lowers binary risk versus a single-asset oncology story and should widen the buyer base to crossover and event-driven funds. If the FDA path for the lead program is credible, the equity can de-risk quickly; if not, the multiple still has to reflect the probability that one of the next two programs becomes the real valuation driver.

The competitive read-through is more interesting than the headline tone suggests. A DLL4/VEGF-A readout, a post-checkpoint CD137 signal, and a PD-1-axis bispecific with activity after CPI all target areas where pharma has been hunting for combinations that can meaningfully move ORR without unacceptable toxicity. That means CMPX’s main strategic asset is not just clinical data, but optionality: each incremental dataset reduces the chance a larger oncology company can dismiss the platform as single-mechanism noise. The flip side is that the field is crowded enough that differentiation will increasingly hinge on tolerability and combination flexibility, not response rate alone.

From a timing perspective, the next 6-12 weeks matter for sentiment, while the 6-18 month window determines fundamental value. The near-term catalyst stack is regulatory interaction on the lead asset and follow-up data on the other programs; the key tail risk is that the market extrapolates early signals before durability and safety are mature enough to support broad adoption. The contrarian issue is that the stock may be underpricing pipeline breadth but overpricing the probability of a clean first approval path, which makes this more attractive as a catalysts-led trade than a long-duration hold.

Key Decisions for Investors

• Go long CMPX into FDA-traceable catalyst windows, but size as a catalyst trade, not a core biotech position; risk/reward is attractive if the market is underestimating approval odds, but downside is steep if interaction details disappoint.
• Buy CMPX calls or call spreads 2-4 months out to capture binary upside from regulatory follow-up and additional clinical data; prefer defined-risk structures because post-event volatility can collapse even on a modestly positive read.
• Pair trade: long CMPX vs. short a later-stage oncology company with a single lead asset and limited pipeline breadth; CMPX has better multi-shot optionality if the market rewards platform de-risking over one-program dependency.
• If CMPX gaps higher on conference enthusiasm, trim into strength and hold a residual position for the next data/regulatory milestone; the risk-reward deteriorates quickly once multiple expansion outruns fundamental confirmation.
• Avoid chasing after a broad biotech rally; enter on pullbacks or ahead of discrete milestones, since the stock’s re-rating depends on event sequencing rather than macro biotech sentiment.